Neurogesx (NGSX) 0.0090 $NGSX
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 312.13 (+8.03), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), DEPO: 30.14 (+2.03), GSK: 42.45 (+0.65)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81)
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 312.13 (+8.03), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), DEPO: 30.14 (+2.03), GSK: 42.45 (+0.65)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81)
